Home LiteratureArticle Details
PMID: 21886458 Published · ppublish English Journal Article

Androgen receptor signaling in prostate cancer development and progression.

Journal of carcinogenesis ·Vol. 10 ·2011-00-00 ·Pages 20

Lonergan PE, Tindall DJ

Abstract

The androgen receptor (AR) signaling axis plays a critical role in the development, function and homeostasis of the prostate. The classical action of AR is to regulate gene transcriptional processes via AR nuclear translocation, binding to androgen response elements on target genes and recruitment of, or crosstalk with, transcription factors. Prostate cancer initiation and progression is also uniquely dependent on AR. Androgen deprivation therapy remains the standard of care for treatment of advanced prostate cancer. Despite an initial favorable response, almost all patients invariably progress to a more aggressive, castrate-resistant phenotype. Considerable evidence now supports the concept that development of castrate-resistant prostate cancer (CRPC) is causally related to continued transactivation of AR. Understanding the critical events and complexities of AR signaling in the progression to CRPC is essential in developing successful future therapies. This review provides a synopsis of AR structure and signaling in prostate cancer progression, with a special focus on recent findings on the role of AR in CRPC. Clinical implications of these findings and potential directions for future research are also outlined.

Keywords
Androgen receptor castrate-resistant prostate cancer signaling
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Lonergan Peter E
Department of Urology, Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, United States of America.
Tindall Donald J
References (155)
155 references, click to expand
  1. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.
    Cell. 2009 Jul 23;138(2):245-56 PMID: 19632176
  2. Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression.
    BMC Cancer. 2005 Jul 22;5:86 PMID: 16042785
  3. Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy?
    Urol Oncol. 2009 Jan-Feb;27(1):67-71 PMID: 19111801
  4. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
    Mol Endocrinol. 2008 Mar;22(3):597-608 PMID: 18079321
  5. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.
    Br J Cancer. 2009 Dec 15;101(12):1949-56 PMID: 19888222
  6. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.
    N Engl J Med. 1995 May 25;332(21):1393-8 PMID: 7723794
  7. Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes.
    Int J Cancer. 2001 May 1;92(3):322-8 PMID: 11291065
  8. Molecular biology of the androgen receptor.
    J Clin Oncol. 2002 Jul 1;20(13):3001-15 PMID: 12089231
  9. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer.
    Cancer Res. 2000 Apr 15;60(8):2290-9 PMID: 10786697
  10. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2.
    Cancer Res. 1999 Sep 1;59(17):4180-4 PMID: 10485450
  11. Interleukin-6: a candidate mediator of human prostate cancer morbidity.
    Urology. 1995 Mar;45(3):542-9 PMID: 7879350
  12. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
    Nat Genet. 2009 May;41(5):619-24 PMID: 19396168
  13. Molecular regulation of androgen action in prostate cancer.
    J Cell Biochem. 2006 Oct 1;99(2):333-44 PMID: 16518832
  14. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study.
    Br J Cancer. 2005 Oct 31;93(9):1019-23 PMID: 16205698
  15. Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis.
    Oncogene. 2007 Jun 28;26(30):4453-63 PMID: 17297473
  16. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
    Lancet. 2010 Apr 24;375(9724):1437-46 PMID: 20398925
  17. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer.
    Clin Cancer Res. 2003 Apr;9(4):1474-9 PMID: 12684422
  18. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer.
    Cancer Res. 2001 Jan 15;61(2):423-7 PMID: 11212224
  19. In vitro gene expression changes of androgen receptor coactivators after hormone deprivation in an androgen-dependent prostate cancer cell line.
    J Formos Med Assoc. 2005 Sep;104(9):652-8 PMID: 16276440
  20. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer.
    Cancer Res. 2007 Jul 15;67(14):6854-62 PMID: 17638896
  21. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.
    Science. 1998 Jan 23;279(5350):563-6 PMID: 9438850
  22. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor.
    Cancer Res. 2006 Nov 15;66(22):11047-54 PMID: 17108144
  23. Androgen receptor in prostate cancer.
    Endocr Rev. 2004 Apr;25(2):276-308 PMID: 15082523
  24. A signature motif in transcriptional co-activators mediates binding to nuclear receptors.
    Nature. 1997 Jun 12;387(6634):733-6 PMID: 9192902
  25. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions.
    Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4562-7 PMID: 12682292
  26. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex.
    Endocr Rev. 2007 Dec;28(7):778-808 PMID: 17940184
  27. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.
    Nat Genet. 2009 May;41(5):524-6 PMID: 19396167
  28. Androgen deprivation increases p300 expression in prostate cancer cells.
    Cancer Res. 2007 Apr 1;67(7):3422-30 PMID: 17409453
  29. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.
    Mod Pathol. 2007 May;20(5):538-44 PMID: 17334343
  30. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy.
    Cancer. 1991 Jun 15;67(12):3057-64 PMID: 1710537
  31. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.
    Endocr Relat Cancer. 2004 Sep;11(3):459-76 PMID: 15369448
  32. SRC-3 is required for prostate cancer cell proliferation and survival.
    Cancer Res. 2005 Sep 1;65(17):7976-83 PMID: 16140970
  33. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer.
    Urology. 1999 Jan;53(1):139-47 PMID: 9886603
  34. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer.
    Am J Pathol. 2002 Oct;161(4):1467-74 PMID: 12368219
  35. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor.
    J Biol Chem. 2000 Jul 28;275(30):22986-94 PMID: 10816582
  36. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells.
    Cancer Res. 2010 Apr 15;70(8):3309-19 PMID: 20388792
  37. Targeting Aurora kinases for the treatment of prostate cancer.
    Cancer Res. 2006 May 15;66(10):4996-5002 PMID: 16707419
  38. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.
    J Biol Chem. 2004 Aug 6;279(32):33438-46 PMID: 15166229
  39. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
    Mol Endocrinol. 2006 May;20(5):1061-72 PMID: 16384856
  40. An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells.
    Mol Cell Endocrinol. 2007 May 30;270(1-2):50-6 PMID: 17374439
  41. Evaluation of ligand-dependent changes in AR structure using peptide probes.
    Mol Endocrinol. 2002 Apr;16(4):647-60 PMID: 11923463
  42. Determinants of target gene specificity for steroid/thyroid hormone receptors.
    Cell. 1989 Jun 30;57(7):1139-46 PMID: 2500251
  43. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
    Cancer. 2005 Jan 1;103(1):76-84 PMID: 15540247
  44. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
    Cancer Res. 2007 Oct 15;67(20):10067-77 PMID: 17942941
  45. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.
    Cancer Res. 2005 Jul 1;65(13):5965-73 PMID: 15994976
  46. In vivo amplification of the androgen receptor gene and progression of human prostate cancer.
    Nat Genet. 1995 Apr;9(4):401-6 PMID: 7795646
  47. Collocation of androgen receptor gene mutations in prostate cancer.
    Clin Cancer Res. 2001 May;7(5):1273-81 PMID: 11350894
  48. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins.
    Mol Cell Biol. 1999 Sep;19(9):6164-73 PMID: 10454563
  49. The role of 5alpha-reduction in steroid hormone physiology.
    Reprod Fertil Dev. 2001;13(7-8):673-8 PMID: 11999320
  50. Interplay between two hormone-independent activation domains in the androgen receptor.
    Cancer Res. 2006 Jan 1;66(1):543-53 PMID: 16397271
  51. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis.
    Cancer Res. 1994 Aug 1;54(15):4096-102 PMID: 7518349
  52. Oncogenic kinase signalling.
    Nature. 2001 May 17;411(6835):355-65 PMID: 11357143
  53. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.
    Prostate. 2001 Jun 15;48(1):47-53 PMID: 11391686
  54. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
    Clin Cancer Res. 2002 Nov;8(11):3438-44 PMID: 12429632
  55. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
    Endocr Relat Cancer. 2009 Mar;16(1):155-69 PMID: 19011039
  56. Mechanisms underlying the development of androgen-independent prostate cancer.
    Clin Cancer Res. 2006 Mar 15;12(6):1665-71 PMID: 16551847
  57. Rapid signalling by androgen receptor in prostate cancer cells.
    Oncogene. 1999 Nov 4;18(46):6322-9 PMID: 10597231
  58. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    J Clin Oncol. 2005 Jan 20;23(3):455-60 PMID: 15659491
  59. Induced chromosomal proximity and gene fusions in prostate cancer.
    Science. 2009 Nov 27;326(5957):1230 PMID: 19933109
  60. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat.
    J Clin Invest. 1996 Dec 1;98(11):2558-63 PMID: 8958218
  61. Expression of NF-kappaB in prostate cancer lymph node metastases.
    Prostate. 2004 Feb 15;58(3):308-13 PMID: 14743471
  62. Cytokine disbalance in common human cancers.
    Biochim Biophys Acta. 2011 Feb;1813(2):308-14 PMID: 21167870
  63. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer.
    Mol Cell Biol. 2002 Apr;22(8):2862-70 PMID: 11909978
  64. Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.
    J Steroid Biochem Mol Biol. 2011 May;125(1-2):32-8 PMID: 20883781
  65. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Cancer Res. 2008 Aug 1;68(15):6407-15 PMID: 18676866
  66. The FXXLF motif mediates androgen receptor-specific interactions with coregulators.
    J Biol Chem. 2002 Mar 22;277(12):10226-35 PMID: 11779876
  67. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells.
    Cancer Res. 2010 Dec 1;70(23):9544-8 PMID: 20947519
  68. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
    Oncogene. 2008 Jun 5;27(25):3596-604 PMID: 18223692
  69. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways.
    J Biol Chem. 2002 Mar 1;277(9):7076-85 PMID: 11751884
  70. Molecular determinants of resistance to antiandrogen therapy.
    Nat Med. 2004 Jan;10(1):33-9 PMID: 14702632
  71. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
    Clin Cancer Res. 2000 Jul;6(7):2702-6 PMID: 10914713
  72. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.
    Mol Cell. 2007 Aug 3;27(3):380-92 PMID: 17679089
  73. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia.
    Cancer Res. 2001 Feb 15;61(4):1686-92 PMID: 11245484
  74. Loss of PTEN is associated with progression to androgen independence.
    Prostate. 2006 Jun 15;66(9):895-902 PMID: 16496415
  75. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase.
    Mol Endocrinol. 2008 Nov;22(11):2420-32 PMID: 18787043
  76. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.
    Br J Cancer. 2003 Aug 4;89(3):552-6 PMID: 12888829
  77. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization.
    Mol Endocrinol. 1991 Oct;5(10):1396-404 PMID: 1775129
  78. Regulation of androgen receptor activity by tyrosine phosphorylation.
    Cancer Cell. 2006 Oct;10(4):309-19 PMID: 17045208
  79. Coactivator selective regulation of androgen receptor activity.
    Steroids. 2009 Aug;74(8):669-74 PMID: 19463689
  80. Compartmentalization of androgen receptor protein-protein interactions in living cells.
    J Cell Biol. 2007 Apr 9;177(1):63-72 PMID: 17420290
  81. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
    J Urol. 1999 Jan;161(1):182-7 PMID: 10037394
  82. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
    Cancer Res. 1998 Oct 15;58(20):4640-5 PMID: 9788616
  83. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
    J Clin Oncol. 2003 Jul 15;21(14):2673-8 PMID: 12860943
  84. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor.
    J Biol Chem. 1995 Mar 31;270(13):7341-6 PMID: 7706276
  85. Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases.
    Clin Cancer Res. 2009 Feb 1;15(3):788-96 PMID: 19188148
  86. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer.
    Am J Pathol. 1994 Apr;144(4):735-46 PMID: 7512791
  87. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
    J Clin Oncol. 2007 Apr 20;25(12):1596-605 PMID: 17404365
  88. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
    Cancer Res. 2006 Mar 15;66(6):3087-95 PMID: 16540658
  89. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.
    Cancer Res. 2004 Dec 15;64(24):9209-16 PMID: 15604294
  90. Targeting the PI3K/AKT pathway for the treatment of prostate cancer.
    Clin Cancer Res. 2009 Aug 1;15(15):4799-805 PMID: 19638457
  91. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.
    Cancer Res. 2009 May 15;69(10):4434-42 PMID: 19366804
  92. The genomic complexity of primary human prostate cancer.
    Nature. 2011 Feb 10;470(7333):214-20 PMID: 21307934
  93. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.
    Urol Oncol. 2013 Jan;31(1):82-6 PMID: 21396844
  94. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.
    Clin Cancer Res. 2010 Jun 1;16(11):3028-34 PMID: 20484019
  95. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling.
    Nucl Recept Signal. 2008 Jun 27;6:e008 PMID: 18612376
  96. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
    Urology. 2006 Oct;68(4):834-9 PMID: 17070363
  97. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
    Clin Cancer Res. 2002 Dec;8(12):3870-6 PMID: 12473602
  98. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.
    Cancer Cell. 2010 Jun 15;17(6):535-46 PMID: 20541699
  99. Cancer statistics, 2010.
    CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 PMID: 20610543
  100. Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines.
    Prostate. 2003 Aug 1;56(3):192-200 PMID: 12772188
  101. Characterization of nuclear import of the domain-specific androgen receptor in association with the importin alpha/beta and Ran-guanosine 5'-triphosphate systems.
    Endocrinology. 2008 Aug;149(8):3960-9 PMID: 18420738
  102. p300 in prostate cancer proliferation and progression.
    Cancer Res. 2003 Nov 15;63(22):7638-40 PMID: 14633682
  103. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
    Endocr Relat Cancer. 2008 Dec;15(4):841-9 PMID: 18667687
  104. Androgen receptor signaling: mechanism of interleukin-6 inhibition.
    Cancer Res. 2004 Apr 1;64(7):2619-26 PMID: 15059919
  105. Activation of mitogen-activated protein kinase associated with prostate cancer progression.
    Cancer Res. 1999 Jan 15;59(2):279-84 PMID: 9927031
  106. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
    Oncogene. 2010 Jun 3;29(22):3208-16 PMID: 20383201
  107. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.
    Prostate. 2005 Apr 1;63(1):19-28 PMID: 15378523
  108. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.
    J Clin Oncol. 2005 Nov 10;23(32):8253-61 PMID: 16278481
  109. Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation.
    J Mol Endocrinol. 2007 Aug;39(2):151-62 PMID: 17693613
  110. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.
    Cancer Res. 1999 Feb 15;59(4):803-6 PMID: 10029066
  111. Contribution of the androgen receptor to prostate cancer predisposition and progression.
    Cancer Metastasis Rev. 2001;20(3-4):207-23 PMID: 12085963
  112. Role of CBP/P300 in nuclear receptor signalling.
    Nature. 1996 Sep 5;383(6595):99-103 PMID: 8779723
  113. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
    Cancer Res. 1994 Oct 15;54(20):5474-8 PMID: 7522959
  114. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.
    Cancer Res. 2001 Jun 1;61(11):4315-9 PMID: 11389051
  115. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis.
    Urology. 2001 Dec;58(6):1008-15 PMID: 11744478
  116. Aurora-A over-expression in high-grade PIN lesions and prostate cancer.
    Prostate. 2005 Sep 1;64(4):341-6 PMID: 15754349
  117. Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain.
    J Biol Chem. 1996 Oct 25;271(43):26772-8 PMID: 8900157
  118. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.
    Cancer Cell. 2003 Sep;4(3):209-21 PMID: 14522255
  119. Interaction of IGF signaling and the androgen receptor in prostate cancer progression.
    J Cell Biochem. 2006 Oct 1;99(2):392-401 PMID: 16639715
  120. Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions.
    Mol Endocrinol. 2008 Oct;22(10):2229-40 PMID: 18451092
  121. Androgen receptors in endocrine-therapy-resistant human prostate cancer.
    Int J Cancer. 1991 May 10;48(2):189-93 PMID: 1708363
  122. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
    Nature. 2007 Aug 2;448(7153):595-9 PMID: 17671502
  123. Structural dynamics of the human androgen receptor: implications for prostate cancer and neurodegenerative disease.
    Biochem Soc Trans. 2006 Dec;34(Pt 6):1098-102 PMID: 17073759
  124. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells.
    Oncogene. 2007 Sep 6;26(41):6061-70 PMID: 17420725
  125. Transcriptional activation and nuclear targeting signals of the human androgen receptor.
    J Biol Chem. 1991 Jan 5;266(1):510-8 PMID: 1985913
  126. Androgen-induced cell migration: role of androgen receptor/filamin A association.
    PLoS One. 2011 Feb 16;6(2):e17218 PMID: 21359179
  127. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer.
    Mol Cell Biol. 1999 Jul;19(7):5143-54 PMID: 10373563
  128. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Carcinogenesis. 2008 Jun;29(6):1148-56 PMID: 18487223
  129. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
    Science. 2005 Oct 28;310(5748):644-8 PMID: 16254181
  130. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways.
    J Biol Chem. 1999 Mar 19;274(12):7777-83 PMID: 10075669
  131. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence.
    Clin Cancer Res. 2004 Oct 1;10(19):6572-8 PMID: 15475446
  132. The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator.
    J Biol Chem. 1999 Jul 16;274(29):20229-34 PMID: 10400640
  133. Interleukin-6 regulation of prostate cancer cell growth.
    J Cell Biochem. 2005 Jun 1;95(3):497-505 PMID: 15838876
  134. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.
    Cancer Res. 2008 Aug 15;68(16):6762-9 PMID: 18701501
  135. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.
    Cancer Res. 1999 Sep 1;59(17):4291-6 PMID: 10485474
  136. Expression of androgen receptor coregulators in prostate cancer.
    Clin Cancer Res. 2004 Feb 1;10(3):1032-40 PMID: 14871982
  137. Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues.
    J Pathol. 2001 Jan;193(1):134-40 PMID: 11169526
  138. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription.
    Mol Cell Biol. 1999 Sep;19(9):6085-97 PMID: 10454556
  139. Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin.
    Mol Endocrinol. 2000 Oct;14(10):1618-26 PMID: 11043577
  140. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.
    J Clin Pathol. 2007 Nov;60(11):1238-43 PMID: 17259299
  141. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
    Cancer Res. 2001 May 1;61(9):3550-5 PMID: 11325816
  142. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer.
    Cancer Res. 2004 Aug 1;64(15):5232-6 PMID: 15289328
  143. The development of androgen-independent prostate cancer.
    Nat Rev Cancer. 2001 Oct;1(1):34-45 PMID: 11900250
  144. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.
    J Clin Endocrinol Metab. 2000 Nov;85(11):4258-65 PMID: 11095464
  145. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer.
    Cell. 2009 Dec 11;139(6):1069-83 PMID: 19962179
  146. Phosphorylation and activation of androgen receptor by Aurora-A.
    J Biol Chem. 2010 Oct 22;285(43):33045-33054 PMID: 20713353
  147. Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs.
    Mol Cancer. 2009 Jul 31;8:57 PMID: 19646263
  148. Steroid receptor coactivator-1 is a histone acetyltransferase.
    Nature. 1997 Sep 11;389(6647):194-8 PMID: 9296499
  149. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate.
    J Urol. 1992 Mar;147(3 Pt 2):798-803 PMID: 1371552
  150. Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
    Science. 2009 May 8;324(5928):787-90 PMID: 19359544
  151. Pleiotropic functional properties of androgen receptor mutants in prostate cancer.
    Hum Mutat. 2009 Feb;30(2):145-57 PMID: 18800375
  152. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
    Br J Cancer. 2001 Dec 14;85(12):1928-36 PMID: 11747336
  153. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability.
    Mol Endocrinol. 1995 Feb;9(2):208-18 PMID: 7776971
  154. Activation of the human androgen receptor through a protein kinase A signaling pathway.
    J Biol Chem. 1996 Aug 16;271(33):19900-7 PMID: 8702703
  155. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.
    Cancer Res. 2001 Mar 1;61(5):1919-26 PMID: 11280747
Article Info
Journal
Journal of carcinogenesis
Abbr.
J Carcinog
ISSN
1477-3163
DOI
10.4103/1477-3163.83937
Published
2011-00-00
Epub
2011-00-23
Pages
20
Language
English
Region
India
NLM ID
101153623
PMCID
PMC3162670
Grants
NCI NIH HHS · P50 CA091956 · United States
NCI NIH HHS · R01 CA121277 · United States
NCI NIH HHS · R01 CA125747 · United States
External Links
PubMed source DOI: 10.4103/1477-3163.83937 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2